drugset / Trial / NCT02133404

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

NCT02133404

Phase 2 Completed 62 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To examine efficacy and safety after 12-week administration of ASP7991 in secondary hyperparathyroidism patients undergoing hemodialysis

Timeline

Start
2014-03-14
Primary completion
2014-11-10
Completion
2014-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP7991 Unknown Oral
Comparator Cinacalcet Other / unclassified Oral